# US 2021/0275488 A1 · Novel compound isolated from cervi parvum cornu, and pharmaceutical uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275488 A1
- Document ID: US20210275488A1
- Status: Published application
- Kind: A1
- Application number: 17/260,592
- Filed: 2019-07-15
- Published: 2021-09-09
- Earliest claimed: 2018-07-16
- Assignees: Fng Research Co., Ltd.
- Applicants: Fng Research Co., Ltd.
- Inventors: Young Sam GOO; Ki Nam SON
- Web page: https://patentgrep.com/patent/US20210275488A1

## CPC

- A23L 33/12: Fatty acids or derivatives thereof
- A61K 31/231: having one or two double bonds
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07C 67/343: by increase in the number of carbon atoms
- C07C 69/30: esterified with trihydroxylic compounds (fats, oils C11B, C11C)
- C07C 69/587: Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present disclosure provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases, leukopenia or neutropenia and a method for synthesizing the same, the pharmaceutical composition including as an active ingredient at least one selected from compounds represented by the Formulas 1 to 4.

## Claims

### Claim 1

A pharmaceutical composition for the prevention or treatment of inflammatory diseases, leukopenia or neutropenia, comprising as an active ingredient at least one selected from compounds represented by the following Formulas 1 to 4.

### Claim 2 (depends on 1)

The pharmaceutical composition for the prevention or treatment of inflammatory diseases, leukopenia or neutropenia as set forth in claim 1,
wherein the active ingredient is a mixture of the compound represented by Formula 1 and the compound represented by Formula 2.

### Claim 3 (depends on 1)

The pharmaceutical composition for the prevention or treatment of inflammatory diseases, leukopenia or neutropenia as set forth in claim 1,
wherein the active ingredient is a mixture of the compound represented by Formula 3 and the compound represented by Formula 4.

### Claim 4 (depends on 1)

The pharmaceutical composition for the prevention or treatment of inflammatory diseases, leukopenia or neutropenia as set forth in claim 1,
wherein the active ingredient inhibits the production of inflammatory cytokines.

### Claim 5 (depends on 1)

The pharmaceutical composition for the prevention or treatment of inflammatory diseases, leukopenia or neutropenia as set forth in claim 1,
wherein the inflammatory disease is selected from the group consisting of atopic dermatitis, edema, dermatitis, allergy, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastritis, colitis, gout, hepatic spondylitis, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, shoulder periarthritis, myositis, hepatitis, cystitis, and nephritis.

### Claim 6 (depends on 1)

The pharmaceutical composition for the prevention or treatment of inflammatory diseases, leukopenia or neutropenia as set forth in claim 1,
wherein the neutropenia disease is neutropenia induced by anticancer chemotherapy drugs.

### Claim 7

A health functional food for preventing or improving inflammatory diseases comprising compounds represented by the following Formulas 1 to 4 as an active ingredient

### Claim 8

A method for synthesizing 1-palmitoyl-2-conjugated linoleoyl-3-acetyl glycerol (PCA glycerol) comprising the steps of:
(a) reacting palmitic acid with a compound represented by the following Formula 5 under basic conditions to synthesize 1-palmitoyl glycerol;
(b) reacting the 1-palmitoyl glycerol with acetyl halide under basic conditions to synthesize 1-palmitoyl-3-acetyl glycerol; and
(c) reacting the 1-palmitoyl-3-acetyl glycerol with conjugated linoleic acid under basic conditions.
(wherein, R1 and R2 are each independently a C1˜C3 alkyl group.)

### Claim 9 (depends on 8)

The method for synthesizing 1-palmitoyl-2-conjugated linoleoyl-3-acetyl glycerol (PCA glycerol) as set forth in claim 8,
wherein in step 1, the palmitic acid is activated by adding pivaloyl halide, or in step (c), the conjugated linoleic acid is activated by adding pivaloyl halide, and the halide is Cl, Br or I.

### Claim 10 (depends on 8)

The method for synthesizing 1-palmitoyl-2-conjugated linoleoyl-3-acetyl glycerol (PCA glycerol) as set forth in claim 8,
wherein the conjugated linoleic acid is a mixture of conjugated linoleic acid (cis-9,trans-11) and conjugated linoleic acid (trans-10,cis-12).

### Claim 11

A method for synthesizing 1-conjugated linoleoyl-2-palmitoyl-3-acetyl glycerol (CPA glycerol) comprising the steps of:
(a) reacting conjugated linoleic acid with a compound represented by the following Formula 5 under basic conditions to synthesize 1-conjugated linoleoyl-glycerol;
(b) reacting the 1-conjugated linoleoyl-glycerol with acetyl halide under basic conditions to synthesize 1-conjugated linoleoyl-3-acetyl glycerol; and
(c) reacting the 1-conjugated linoleoyl-3-acetyl glycerol with palmitic acid under basic conditions.
(wherein, R1 and R2 are each independently a C1˜C3 alkyl group.)

### Claim 12 (depends on 11)

The method for synthesizing 1-conjugated linoleoyl-2-palmitoyl-3-acetyl glycerol (CPA glycerol) as set forth in claim 11,
wherein in step (a), the conjugated linoleic acid is activated by adding pivaloyl halide, or in step (c), the palmitic acid is activated by adding pivaloyl halide, and the halide is Cl, Br or I.

### Claim 13 (depends on 11)

The method for synthesizing 1-conjugated linoleoyl-2-palmitoyl-3-acetyl glycerol (CPA glycerol) as set forth in claim 11,
wherein the conjugated linoleic acid is a mixture of conjugated linoleic acid (cis-9,trans-11) and conjugated linoleic acid (trans-10,cis-12).
